Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

124.21 -4.93 (-3.82%)
Streaming Delayed Price Updated: 1:12 PM EDT, Oct 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
50 51 Next >
Stock Market Rally Breaks Higher; Tesla, Netflix, Snap, United Airlines Key Earnings: Weekly Review
But a slew of earnings reports and another big Fed rate hike loom. 
Via Investor's Business Daily
New Indication Approval For Incyte "To Usher New Growth Avenue"
 
Via Benzinga
HC Wainwright Starts Coverage On This 'Best-In-Class Agent For Inflammatory Disorders
 
Via Benzinga
Ford, General Motors Rally; Check These Other Big Gainers From Yesterday
U.S. stocks closed sharply higher, with the Dow Jones gaining more than 750 points on Tuesday. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Recap: Novartis Q2 Earnings
  Novartis (NYSE:NVS) reported its Q2 earnings results on Tuesday, July 19, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Novartis Resumes Production, Delivery Of Radioligand Therapy Medicines
 
Via Benzinga
Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday
Gainers Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and... 
Via Benzinga
This Financial Services Stock Is Trading Higher By 50%, Here Are 40 Stocks Moving In Tuesday's Mid-Day Session
Gainers Applied Blockchain, Inc. (NASDAQ: APLD) jumped 50.1% to $1.5907 after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue... 
Via Benzinga
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Novartis Beats Second-Quarter Earnings Goal But Sales Light
Swiss drugmaker Novartis on Tuesday delivered better-than-expected earnings for the second quarter but sales were light. Novartis stock rose. 
Via Investor's Business Daily
IBM And 20 Stocks Moving Premarket
Gainers Applied Blockchain, Inc. (NASDAQ: APLD) rose 32.1% to $1.40 in pre-market trading after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised... 
Via Benzinga
Novartis Posts Mixed Q2 Earnings, Expects Improved Earnings At Sandoz
 
Via Benzinga
Earnings Preview For Novartis
Novartis (NYSE:NVS) is set to give its latest quarterly earnings report on Tuesday, 2022-07-19. Here's what investors need to know before the announcement. Analysts estimate that Novartis will report... 
Via Benzinga
Tesla, Twitter, Goldman Among Headline Earnings Of Unfolding Week: Here Are The Key Earnings Ahead
The June quarter reporting season is entering its second week, with the focus gradually shifting from banks to technology companies. 
Via Benzinga
Stock Market Overview For The Week Of July 18, 2022
This past week we got new red-hot CPI numbers, further drama in the Elon Musk and Twitter saga, and the start of earnings season. 
Via Talk Markets
Aurinia Pharmaceuticals Skids With Its Buyout Thesis Hanging By A Thread
The company just hired three new executives, likely putting a buyout in the rearview. 
Via Investor's Business Daily
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Novartis AG with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Novartis AG with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Beigene's Inspections Delay Suggest Eventual Approval, Says This Analyst
Beigene Limited (NASDAQ: BGNE) provided a regulatory update on the anticipated US approval decision for the Biological License Application for tislelizumab in 2L metastatic esophageal squamous cell... 
Via Benzinga
Global Liposarcoma Treatment Market 2022 Business Strategies and Overview Report 2031 Taro Pharmaceuticals, Sandoz, Pfizer, Eli Lilly, Sanofi SA, Novartis AG
The intelligent report on the global Liposarcoma Treatment market provides deep analysis of the Liposarcoma Treatment industry segments including product type, application, special geographies and... 
Via SBWire
Topics Supply Chain
The Healthcare Companies Fighting the World’s Biggest Killers
Palm Beach, FL – July 13, 2022 – FinancialNewsMedia.com News Commentary – Some of the most prevalent health conditions on the planet claim millions of lives every year. Companies from across the... 
Via FinancialNewsMedia
Liposome Drug Delivery Market Size, Share, Key Players Analysis, Growth Factors, New Technology, Application and Regional Forecast to 2028
Global Liposome Drug Delivery Market Size was estimated at USD 3316.64 million in 2021 and is projected to reach USD 7768.01 million by 2028, exhibiting a CAGR of 12.93% during the forecast period 
Via SBWire
AstraZeneca's COVID-19 Treatment Allowed In China's Southern City: Reuters
 
Via Benzinga
Dry Eye Syndrome Treatment Market Size, Share, Key Players Analysis, Growth Factors, New Technology, Application and Regional Forecast to 2028
Global Dry Eye Syndrome Treatment Market Size was estimated at USD 3062.77 million in 2021 and is projected to reach USD 3959.59 million by 2028, exhibiting a CAGR of 3.74% during the forecast period 
Via SBWire
Global PCSK9 Inhibitors Market |Key players are Amgen, Eli Lilly, Sanofi, Pfizer, Novartis, Roche, Merck, Alnylam, AstraZeneca, Affiris, BMS, Ionis Pharmaceuticals, Cyon Therapeutics, and Daiichi Sankyo.
Global PCSK9 Inhibitors Market |Key players are Amgen, Eli Lilly, Sanofi, Pfizer, Novartis, Roche, Merck, Alnylam, AstraZeneca, Affiris, BMS, Ionis Pharmaceuticals, Cyon Therapeutics, and Daiichi... 
Via iCrowdNewswire
Antifungal Drugs Market Import-Export Details, Production Information 2022-2029 : Sanofi-Aventis, Novartis, Pfizer Inc, Abbott Laboratories
Global Antifungal Drugs Market Research 2022-2031 published by Calibre Research studies the current situation, Antifungal Drugs market size, share, trends, regional growth and the latest technologies... 
Via SBWire
Topics Supply Chain
Celldex Therapeutics Skids As It Takes On A Blockbuster Roche, Novartis Drug
The study was in 26 patients with chronic hives that don't respond to antihistamines. 
Via Investor's Business Daily
Cough Remedies Market 2022-2029 Global Industry Trends, Growth Rate and Revenue : Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis
Global Cough Remedies Market Research 2022-2031 published by Calibre Research studies the current situation, Cough Remedies market size, share, trends, regional growth and the latest technologies... 
Via SBWire
Topics Supply Chain
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Novartis' Tislelizumab Extends Overall Survival In Late-Stage Esophageal Cancer Study
Novartis AG (NYSE: NVS) announced results from the Phase 3 RATIONALE 306 trial of tislelizumab plus chemotherapy in patients with unresectable, locally advanced recurrent or metastatic esophageal... 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
50 51 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.